VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Aug 9, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-08-07

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-07	Common Stock	M	4250	$77.31	Acquired	125367	Direct
2017-08-07	Common Stock	S	4250	$152.88	Disposed	121117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-07	Stock Option (Right to Buy)	$77.31	M	4250	Disposed	2024-02-04	Common Stock (4250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.

F2: The option vests in 16 quarterly installments from 2/5/2014.